49755-48-8Relevant articles and documents
Compound for preparing baloxavir or derivatives thereof as well as preparation method and application of compound
-
Paragraph 0200-0203; 0211-0214, (2021/02/10)
The invention relates to a preparation method of a compound shown as a formula VIII for preparing baloxavir or derivatives thereof, a compound shown as a formula I for preparing the compound shown asthe formula VIII and a preparation method of the compound shown as the formula I. The compound shown as the formula I is used for preparing the compound shown as the formula VIII, the baloxavir or thederivative thereof. The preparation method is simple and convenient to operate, and the raw materials are easily available and low in cost; reaction conditions are mild, and the method is safe and environment-friendly; side reactions are few, and the product purity is high; and the quality is controllable, and the method is suitable for industrial production.
ANTI-BACTERIAL COMPOUNDS
-
Page/Page column 104; 105, (2017/06/28)
A compound of Formula (II): for use in the prevention or treatment of a bacterial infection.
Arylthio compounds
-
, (2008/06/13)
Arylthiol and dithiobisarylamide antibacterial and antiviral agents have the general formula STR1 where A is monocyclic or bicyclic aryl which can contain up to 3 heteroatoms selected from O, S, and N, R1 and R2 are substituent groups, X is STR2 or SO2 NR4 Z, Y is H or SZ when n is 1, a single bond when n is 2; R4 and Z can be hydrogen or alkyl.
A new class of anti-HIV-1 agents targeted toward the nucleocapsid protein NCp7: The 2,2'-dithiobisbenzamides
Domagala, John M.,Bader, John P.,Gogliotti, Rocco D.,Sanchez, Joseph P.,Stier, Michael A.,Song, Yuntao,Vara Prasad,Tummino, Peter J.,Scholten, Jeffrey,Harvey, Patricia,Holler, Tod,Gracheck, Steve,Hupe, Donald,Rice, William G.,Schultz, Robert
, p. 569 - 579 (2007/10/03)
As part of the National Cancer Institute's Drug Screening Program, a new class of antiretrovirals active against the human immunodeficiency virus HIV-1 has been identified, and the HIV-1 nucleocapsid protein NCp7 was proposed as the target of antiviral action. The 2,2'-dithiobis-[4'-(sulfamoyl)benzanilide] (3x) and the 2,2'-dithiobis(5-acetylamino)benzamide (10) represented the prototypic lead structures. A wide variety of 2,2'-dithiobisbenzamides were prepared and tested for anti-HIV-1 activity, cytotoxicity, and their ability to extrude zinc from the zinc fingers for NCp7. The structure-activity relationships demonstrated that the ability to extrude zinc from NCp7 resided in the 2,2'-dithiobisbenzamide core structure. The 3,3' and the 4,4' isomers were inactive. While many analogs based upon the core structure retained the zinc extrusion activity, the best overall anti-HIV-1 activity was only found in a narrow set of derivatives possessing carboxylic acid, carboxamide, or phenylsulfonamide functional groups. These functional groups were more important for reducing cytotoxicity than improving antiviral potency or activity vs NCp7. All of the compounds with antiviral activity also extruded zinc from NCp7. From this study several classes of low μM anti-HIV agents with simple chemical structures were identified as possible chemotherapeutic agents for the treatment of AIDS.
Antithrombotic agent
-
, (2008/06/13)
Certain 2,2'-dithiobis-N-substituted or unsubstituted benzamides or derivatives thereof are useful as antithrombotic agents because of their ability to suppress aggregation of blood platelets.
STUDIES ON ORGANOPHOSPHORUS COMPOUNDS. THIATION OF 3,1-BENZOXATHIAN-4-ONES. NEW ROUTES TO 1,2-BENZISOTHIAZOLE-3(2H)-THIONES AND 3H-1,2-BENZODITHIOL-3-IMINES
El-Barbary, A. A.,Clausen, K.,Lawesson, S.-O.
, p. 3309 - 3316 (2007/10/02)
3,1-Benzoxathian-4-ones, 2, when heated with 2,4-bis(4-methoxyphenyl)-1,3,2,4-dithiadiphosphetane-2,4-disulfide, 1, or with P4S10 give one or more of the following products: 3,1-benzoxathian-4-thione, 3, 1,3-benzodithian-4-one, 4, 1,3-benzodithian-4-thion
